Clinical Deterioration Following Improvement in the NINDS rt-PA Stroke Trial

Background and Purpose— Little is known in regard to cerebral arterial reocclusion after successful thrombolysis. In the absence of arteriographic information, the National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Trial investigators prospectively identified clinical deterioration following improvement (DFI) as a possible surrogate marker of cerebral arterial reocclusion after rt-PA–induced recanalization. Also, we identified any significant clinical deterioration (CD) even if not preceded by improvement. This observational analysis was designed to determine the incidence of DFI and CD in each treatment group, to identify baseline or posttreatment variables predictive of DFI or CD, and to determine any relationship between DFI, CD, and clinical outcome. Methods— DFI was defined as any 2-point deterioration on the NIH Stroke Scale after an initial 2-point improvement after treatment. CD was defined as any 4-point worsening after treatment compared with baseline. All data were collected prospectively by investigators blinded to treatment allocation. A noncontrast brain CT was mandated when a 2-point deterioration occurred. All cases were validated by a central review committee. Results— DFI was identified in 81 of the 624 patients (13%); 44 were treated with rt-PA and 37 were treated with placebo (P =0.48). DFI occurred more often in patients with a higher baseline NIH Stroke Scale score. CD within the first 24 hours occurred in 98 patients (16% of all patients); 43 were given rt-PA and 55 were given placebo (P =0.19). Baseline variables associated with CD included a less frequent use of prestroke aspirin and a higher incidence of early CT changes of edema or mass effect or dense middle cerebral artery sign. Patients with CD had higher rates of increased serum glucose and fibrin degradation products, and they also had higher rates of symptomatic intracranial hemorrhage and death. Patients who experienced either DFI or CD were less likely to have a 3-month favorable outcome. Conclusions— We found no association between DFI, CD, and rt-PA treatment, and no clinical evidence to suggest reocclusion. Deterioration was strongly associated with stroke severity and poor outcome and was less frequent in patients whose stroke occurred while they were on aspirin.

[1]  R. Ojemann,et al.  Thresholds of focal cerebral ischemia in awake monkeys. , 1981, Journal of neurosurgery.

[2]  J. Grotta,et al.  Does platelet antiaggregant therapy lessen the severity of stroke? , 1985, Neurology.

[3]  P. Lyden,et al.  Tissue Plasminogen Activator: Reduction of Neurologic Damage After Experimental Embolic Stroke , 1988 .

[4]  G. Lenzi,et al.  Clinical and instrumental evaluation of patients with ischemic stroke within the first six hours , 1989, Journal of the Neurological Sciences.

[5]  J. Burns,et al.  Orbital evolution of circumplanetary dust by resonant charge variations , 1988, Nature.

[6]  A. Dávalos,et al.  Deteriorating ischemic stroke , 1990, Neurology.

[7]  J. Marler,et al.  Urgent Therapy for Stroke: Part II. Pilot Study of Tissue Plasminogen Activator Administered 91-180 Minutes From Onset , 1992, Stroke.

[8]  J. Broderick,et al.  Urgent Therapy for Stroke: Part I. Pilot Study of Tissue Plasminogen Activator Administered Within 90 Minutes , 1992, Stroke.

[9]  峰松 一夫.  Spectacular shrinking deficit : rapid recovery from a major hemispheric syndrome by migration of an embolus , 1993 .

[10]  M. Ginsberg,et al.  The ischemic penumbra, injury thresholds, and the therapeutic window for acute stroke , 1994, Annals of neurology.

[11]  T. Olsen,et al.  Effect of blood pressure and diabetes on stroke in progression , 1994, The Lancet.

[12]  Sidney Strickland,et al.  Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator , 1995, Nature.

[13]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[14]  Koroshetz Wj,et al.  Tissue plasminogen activator for acute ischemic stroke. , 1996, The New England journal of medicine.

[15]  C. Pozzilli,et al.  Progressing neurological deficit secondary to acute ischemic stroke. A study on predictability, pathogenesis, and prognosis. , 1995, Archives of neurology.

[16]  W. Feinberg,et al.  Hemostatic markers in acute ischemic stroke. Association with stroke type, severity, and outcome. , 1996, Stroke.

[17]  Peter Sandercock,et al.  The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke , 1997, The Lancet.

[18]  Zheng-Ming Chen,et al.  CAST: randomised placebo-controlled trial of early aspirin use in 20 000 patients with acute ischaemic stroke , 1997, The Lancet.

[19]  G. Schlaug,et al.  Enlargement of human cerebral ischemic lesion volumes measured by diffusion‐weighted magnetic resonance imaging , 1997, Annals of neurology.

[20]  T. N. t-P. S. S. Group,et al.  Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the NINDS t-PA Stroke Trial. , 1997, Stroke.

[21]  J. Grotta,et al.  Reperfusion Injury: Demonstration of Brain Damage Produced by Reperfusion after Transient Focal Ischemia in Rats , 1997, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[22]  T. N. t-P. S. S. Group,et al.  Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group. , 1997, Stroke.

[23]  J. Grotta,et al.  Hypertension and its treatment in the NINDS rt-PA Stroke Trial. , 1998, Stroke.

[24]  A. Alexandrov,et al.  tPA-associated reperfusion after acute stroke demonstrated by SPECT. , 1998, Stroke.

[25]  E. Antman,et al.  Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. , 1999, Circulation.

[26]  E. Lesaffre,et al.  Neurological deterioration in acute ischemic stroke: potential predictors and associated factors in the European cooperative acute stroke study (ECASS) I. , 1999, Stroke.

[27]  A. Demchuk,et al.  Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke. , 1999, Stroke.

[28]  A. Alexandrov,et al.  Deterioration following spontaneous improvement : sonographic findings in patients with acutely resolving symptoms of cerebral ischemia. , 2000, Stroke.